RayKnowChina Research Map
Shortlist0

Not yet recruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Shanghai Chest Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Shanghai Chest Hospital上海市胸科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06861894, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Esophageal squamous cell carcinoma confirmed by histology or cytology.

    Inclusion criterion 2

    Thoracic esophageal squamous cell carcinoma confirmed by CT or pet-CT, which is classified as cII-III (AJCC 8th).

    Inclusion criterion 3

  3. not comply with cⅡ-Ⅲ(cT2N1-2M0 or cT3N0-2M0, AJCC 8th)

    Exclusion criterion 9

  4. Subjects with other malignant tumors within 5 years before the first administration, but subjects with cervical carcinoma in situ, skin basal cell carcinoma, skin squamous cell carcinoma, localized prostate cancer received radical surgery and ductal carcinoma in situ that have received radical treatment and do not need other treatment can be included)

    Exclusion criterion 10

  5. ECOG PS: 0\~1.

    Inclusion criterion 6

  6. HIV-positive or active hepatitis B (HBsAg positive and HBV-DNA ≥2000 IU/ml or ≥ 104 copies/mL) or active hepatitis C (HCV antibody positive) or active tuberculosis

    Exclusion criterion 16

  7. Women of childbearing age must undergo a serological pregnancy test within 72 hrs before first administration. Women of childbearing age, or male subjects with childbearing age female partners, must take contraceptive measures from the first dose to three months after last administration.

    Inclusion criterion 10

    Pregnant or breastfeeding female

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06861894, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Subjects signed the informed consent and volunteered to participate in the study.
  • Esophageal squamous cell carcinoma confirmed by histology or cytology.
  • Thoracic esophageal squamous cell carcinoma confirmed by CT or pet-CT, which is classified as cII-III (AJCC 8th).
  • Expect to have R0 resection
  • In age from 18 to 75.
  • ECOG PS: 0\~1.
  • Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
  • No contraindications to surgery.
  • Has sufficient organ function including (1) Blood routine: NE≥1.5×109/L; PLT≥100×109/L; HGB≥90 g/L (2)Comprehensive Metabolic Panel: bilirubin≤ 1.5×ULN; ALT≤2.5×ULN; AST≤2.5×ULN; sCr≤1.5×ULN or CrCl≥50 mL/min(Cocheroft-Gault) (3) Coagulation function: INR≤1.5; APTT≤1.5×ULN
  • Women of childbearing age must undergo a serological pregnancy test within 72 hrs before first administration. Women of childbearing age, or male subjects with childbearing age female partners, must take contraceptive measures from the first dose to three months after last administration.
  • Good compliance, willing to comply with follow-up schedules.

Exclusion Criteria:

  • Subjects have received or are receiving any of:
  • anti-tumor interventions such as radiotherapy, chemotherapy, or other medications.
  • immunosuppressants or systemic glucosteroids (prednisone equivalence> 10mg/d) within 2 weeks before the first administration, inhaled or topical use of glucosteroids (prednisone equivalence>10mg/d) is allowed if no known active autoimmune disease.
  • live vaccine within 4 weeks before the first administration.
  • major surgery or major injury within 4 weeks before the first administration.
  • Cancer-related exclusion criteria
  • other cancers instead of ESCC
  • unresectable or metastatic ESCC
  • not comply with cⅡ-Ⅲ(cT2N1-2M0 or cT3N0-2M0, AJCC 8th)
  • Subjects with other malignant tumors within 5 years before the first administration, but subjects with cervical carcinoma in situ, skin basal cell carcinoma, skin squamous cell carcinoma, localized prostate cancer received radical surgery and ductal carcinoma in situ that have received radical treatment and do not need other treatment can be included)
  • Other criteria
  • Subjects have uncontrolled cardiovascular diseases, such as 1) heart failure ≥ NYHA class 2, 2) unstable angina 3) myocardial infarction within 1 year; 4) supraventricular or ventricular arrhythmia that needs treatment
  • Subjects with any known active autoimmune disease
  • Pregnant or breastfeeding female
  • Presence of allergy or hypersensitivity to investigational medications
  • HIV-positive or active hepatitis B (HBsAg positive and HBV-DNA ≥2000 IU/ml or ≥ 104 copies/mL) or active hepatitis C (HCV antibody positive) or active tuberculosis
  • Investigators assessed there might be other factors that cause subjects to withdraw.

Quoted from ClinicalTrials.gov, NCT06861894, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06861894, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06861894